- Androgen Deprivation Therapy for Prostate Cancer
Androgen Deprivation Therapy for Prostate Cancer
Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment. ADT has shown survival benefit in some patients but it also has been associated with some adverse health effects and a possible link to neurocognitive dysfunction.
A new study published online by JAMA Oncology uses an informatics approach with a text-processing method to analyze electronic medical records data to examine ADT and the subsequent development of dementia (senile dementia, vascular dementia, frontotemporal dementia and Alzheimer dementia).
Kevin T. Nead, M.D., M.Phil., formerly of the Stanford University School of Medicine, California, and now the University of Pennsylvania Perelman School of Medicine, Philadelphia, and coauthors used data from an academic medical center from 1994 to 2013. The final study group included 9,272 men with prostate cancer, including 1,862 (19.7 percent) who received ADT.
The authors report there were 314 new cases of dementia during a media follow-up of 3.4 years with a median time to dementia of four years.
The absolute increased risk of developing dementia among those men who received ADT was 4.4 percent at five years, according to the results. Further analysis suggests men who received ADT at least 12 months had the greatest absolute increased risk of dementia. Men 70 or older who received ADT were the least likely to remain dementia free.
The report suggests several plausible mechanisms to explain an association between ADT and dementia in general, including that androgens have a demonstrated role in neuron health and growth.
Study limitations include using clinical text documentation and billing codes to determine a diagnosis of dementia. Because of its design, the study also cannot determine a causal association between the use of ADT and the risk of dementia.
“Our study extends previous work supporting an association between use of ADT and Alzheimer disease and suggests that ADT may more broadly affect neurocognitive function. This finding should be investigated in prospective studies given significant individual patient and health system implications if there are higher rates of dementia among the large groups of patients undergoing ADT,” the study concludes.
(JAMA Oncol. Published online October 13, 2016. doi:10.1001/jamaoncol.2016.3662.
DISCLAIMER: Bankix Systems Ltd is the registered name of a Canadian firm since 2003, and bankixsystems.com is its OFFICIAL website. Besides these entities, we have no relationship with anyone, business, website, or any other entity anywhere in the world, claiming to be Bankix Systems, or using a similar name, and creating the impression that it has some connection with our company. We do not endorse and are therefore, not responsible for any act or lack thereof by any such entity. Bankix Systems Ltd is also not responsible for the content of the description of products and services linked to our site nor does it necessarily endorse them. The information here provided is not for diagnosing/treating your health concerns. Kindly contact your doctor or health care professional for all your healthcare requirements.
Contents © 2003-2019, BankixSystems.com. All rights reserved. Unauthorized reproduction strictly prohibited. Information based on best available resources. Opinions are current and subject to change.